Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 1;15(2):481. doi: 10.3390/pharmaceutics15020481

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Design of a neuroendocrine prostate cancer (NEPC)-targeted chemotheranostic prodrug conjugate, DOTA-PEG₃-TZ(PEG₄-Octr)-PEG₂-Trz-PEG₃-Val-Cit-pABOC-FTY720. DOTA: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; PEG_n: polyethylene glycol chain with n repeating ethyleneoxy units (n = 2, 3, or 4); TZ: 1,3,5-triazine; Octr: octreotide; Trz: 1,4-disubstituted 1,2,3-triazole; Val: valine; Cit: citrulline; pABOC: p-amino-benzyloxycarbonyl; FTY720: fingolimod; T-SMPDC: theranostic small-molecule prodrug conjugate.